Wall Street Zen Upgrades Cardiol Therapeutics to Hold

Got story updates? Submit your updates here. ›

Wall Street Zen investment analysts have upgraded shares of Cardiol Therapeutics (NASDAQ:CRDL) from a 'sell' rating to a 'hold' rating in a new research note. The upgrade comes as the clinical-stage pharmaceutical company continues to advance its lead asset, CardiolRx, a proprietary cannabidiol (CBD) formulation targeting inflammation and oxidative stress in cardiovascular disease.

Why it matters

Cardiol Therapeutics has been working to develop innovative treatments for patients with cardiovascular conditions. The upgrade from Wall Street Zen, while still a 'hold' rating, represents a positive shift in sentiment around the company's prospects as it progresses its pipeline.

The details

In the research note, Wall Street Zen analysts cited Cardiol Therapeutics' ongoing clinical development of CardiolRx, which has been evaluated in a Phase 2 myocardial protection study. The analysts also noted the company's exclusive global licensing rights to the CardiolRx formulation. The upgrade comes after several other equity analysts have weighed in on Cardiol Therapeutics, with one maintaining a 'buy' rating and another a 'sell' rating, resulting in an average analyst rating of 'hold'.

• Cardiol Therapeutics stock opened at $1.41 on Friday, April 5, 2026.
• The company's 50-day moving average price is $1.06 and its 200-day moving average price is $1.05.